GLPG 0974

Drug Profile

GLPG 0974

Alternative Names: GLPG-0974

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator Galapagos NV; GlaxoSmithKline
  • Developer Galapagos NV
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action G-protein coupled receptor 43 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 No development reported - Phase-I for Inflammatory bowel disease (In volunteers) in Belgium (PO)
  • 10 Feb 2016 No development reported - Phase-II for Ulcerative colitis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top